The new normal in healthcare:
Flourishing in ‘the new normal’ requires the thoughtful integration of business strategy and external engagement across the full range of partners, to create and sustain markets for progress in medicine.
Galen/Atlantica specializes in:
We developed a policy strategy for a world leader in oncology to align the company’s external engagement with the cutting-edge science and commercial priorities for its largest therapeutic area.
We worked with the UK government to lead a 30-nation Summit of scientists and policymakers to prioritize 25 policy responses to antimicrobial resistance across human health and agriculture. The Summit outputs informed the 2016 UN High Level Meeting agenda on the topic.
We developed the policy and collaboration strategy to support the conditions for health systems to take up and use a disease-modifying treatment for Alzheimer’s disease.
FFMatt Diver and Nicholas Gertler founded Galen/Atlantica in Boston in 2015 after serving as partners at Tapestry Networks, where they led collaborations of senior executives of the pharmaceutical industry, government agencies, civil society and KOLs to advance responsive and sustainable healthcare innovation.
Matt’s career spans service as a Peace Corps Volunteer in Africa, as an investment banker focused on the technology sector, and a manager at BCG. He holds a business degree from UC Berkeley and a master’s in public policy from Harvard’s Kennedy School.
Before his time at Tapestry, Nicholas was head of the CEO’s office of a $5B technology company, a McKinsey consultant, and an attorney in the Washington, DC office of Latham & Watkins. He holds masters’ in engineering and policy from the Massachusetts Institute of Technology and a JD from Harvard Law.
In many clinical situations doctors need to treat patients with antibiotics without knowing what is causing their symptoms. This leads to widespread use of antibiotics where they are not needed, and the risk of using the wrong antibiotic where one is needed.
The widespread adoption of faster and more accurate diagnostics would address this problem, but their development and introduction has been slow. Part of what’s missing has been a way to clearly define the different jobs to be done by diagnostics and the target performance characteristics they need to deliver.
The workshop also identified four distinct diagnostic typologies in infectious disease, along with the different performance characteristics required from each category. This much-needed specificity serves as a roadmap for clinicians, patients, technology developers, and policy-makers.
Copyright © 2015 Galen-Atlantica